Tuesday, August 16, 2022 3:04:31 PM
GM-CSF is responsible for the cytokine storm. The cytokine storm is responsible for severe Covid and death. Administering lenzilumab after a patient is already hypoxic isn't ideal. The cytokine storm is already on full blast. Once the cytokine storm is on full blast, there are already many other cytokines triggered. The LIVE-AIR trial had 720% efficacy on the primary endpoint for the patients with a CRP<41mg/L. That represented 25% of the patients in the trial. The ACTIV-5 trial might still have great data with those patients. It will be nice when Humanigen has that data to analyze. It will also be nice if they can do a trial for moderate patients. GM-CSF is upstream. Treating it early is obviously ideal.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM